Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | July 27, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dyne Therapeutics, Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,586,796 |
Last balance in matching sequence
After 2026-07-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-27 · Sale · Disposed 256,072 · Balance 3,592,184 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Row 2 · 2026-07-27 · Sale · Disposed 5,388 · Balance 3,586,796 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. F4: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. ("ForDyne") on November 11, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
F3: The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") and Forbion Growth Opportunities Fund II Cooperatief U.A. ("FGO II"). Forbion IV Management B.V. ("Forbion Management") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.
F4: (Continued from Footnote 3) Forbion Growth II Management B.V. ("FGO II Management"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 18, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,320 | $35.04 | $46,252.80 |
DisclosureSEC source: 0000950170-24-107768 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 397,103 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| September 05, 2024 Filed Sep 9, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,577 | $35.03 | $55,242.31 |
DisclosureSEC source: 0000950170-24-104738 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 398,423 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 6,204 | $46.01 | $285,446.04 |
DisclosureSEC source: 0000950170-24-103382 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 400,000 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.89 to $46.26, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 25,096 | $45.49 | $1,141,617.04 |
DisclosureSEC source: 0000950170-24-103382 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 406,204 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.885 to $45.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 10,768 | $45.81 | $493,282.08 |
DisclosureSEC source: 0000950170-24-102326 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 431,300 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.66 to $46.03, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 45,640 | $45.19 | $2,062,471.60 |
DisclosureSEC source: 0000950170-24-102326 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 442,068 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.65 to $45.63, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 61,467 | $44.94 | $2,762,326.98 |
DisclosureSEC source: 0000950170-24-102326 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 487,708 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.76 to $45.11, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 16,386 | $44.41 | $727,702.26 |
DisclosureSEC source: 0000950170-24-102326 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 549,175 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.76 to $44.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 65,403 | $44.28 | $2,896,044.84 |
DisclosureSEC source: 0000950170-24-101378 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 565,561 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.79 to $44.67, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 11,534 | $45.79 | $528,141.86 |
DisclosureSEC source: 0000950170-24-101378 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 630,964 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.71 to $46.16, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 77,963 | $45.23 | $3,526,266.49 |
DisclosureSEC source: 0000950170-24-101378 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 642,498 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.71 to $45.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 64,133 | $46.37 | $2,973,847.21 |
DisclosureSEC source: 0000950170-24-100532 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 720,461 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.14 to $46.76, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 20,955 | $45.82 | $960,158.10 |
DisclosureSEC source: 0000950170-24-100532 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 784,594 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.14 to $46.13, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 413 | $46.97 | $19,398.61 |
DisclosureSEC source: 0000950170-24-100532 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 805,549 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.76 to $47.06, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 94,908 | $45.82 | $4,348,684.56 |
DisclosureSEC source: 0000950170-24-100532 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 805,962 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.45 to $46.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 71,245 | $47.01 | $3,349,227.45 |
DisclosureSEC source: 0000950170-24-099831 · ownership.xml · nonDerivative · entry 5 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 900,870 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.86 to $47.34, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 64,518 | $46.52 | $3,001,377.36 |
DisclosureSEC source: 0000950170-24-099831 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 972,115 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.86 to $46.85, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 8,326 | $47.30 | $393,819.80 |
DisclosureSEC source: 0000950170-24-099831 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,036,633 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $47.25 to $47.38, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 35,457 | $46.94 | $1,664,351.58 |
DisclosureSEC source: 0000950170-24-099831 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,044,959 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.25 to $47.24, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 43,057 | $45.68 | $1,966,843.76 |
DisclosureSEC source: 0000950170-24-099831 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,080,416 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.21 to $46.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 5,760 | $46.59 | $268,358.40 |
DisclosureSEC source: 0000950170-24-099071 · ownership.xml · nonDerivative · entry 6 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,123,473 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.55 to $46.64, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 89,824 | $46.01 | $4,132,802.24 |
DisclosureSEC source: 0000950170-24-099071 · ownership.xml · nonDerivative · entry 5 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,129,233 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.55 to $46.54, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 30,448 | $45.10 | $1,373,204.80 |
DisclosureSEC source: 0000950170-24-099071 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,219,057 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.55 to $45.54, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 3,072 | $46.19 | $141,895.68 |
DisclosureSEC source: 0000950170-24-099071 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,249,505 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.13 to $46.20, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 85,086 | $45.35 | $3,858,650.10 |
DisclosureSEC source: 0000950170-24-099071 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,252,577 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.01 to $45.99, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 34,485 | $44.52 | $1,535,272.20 |
DisclosureSEC source: 0000950170-24-099071 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,337,663 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.00 to $44.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 49,601 | $45.67 | $2,265,277.67 |
DisclosureSEC source: 0000950170-24-098052 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,372,148 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.56 to $45.89, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 131,290 | $45.25 | $5,940,872.50 |
DisclosureSEC source: 0000950170-24-098052 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,421,749 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.56 to $45.55, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 100,650 | $43.67 | $4,395,385.50 |
DisclosureSEC source: 0000950170-24-098052 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,553,039 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.23 to $44.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 21,428 | $43.57 | $933,617.96 |
DisclosureSEC source: 0000950170-24-097031 · ownership.xml · nonDerivative · entry 5 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,653,689 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.26 to $44.24, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 88,179 | $42.78 | $3,772,297.62 |
DisclosureSEC source: 0000950170-24-097031 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,675,117 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.25 to $43.24, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 24,378 | $42.08 | $1,025,826.24 |
DisclosureSEC source: 0000950170-24-097031 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,763,296 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.95 to $42.23, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 52,076 | $43.42 | $2,261,139.92 |
DisclosureSEC source: 0000950170-24-097031 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,787,674 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.105 to $44.09, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 26,416 | $42.74 | $1,129,019.84 |
DisclosureSEC source: 0000950170-24-097031 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,839,750 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.09 to $43.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,160 | $44.04 | $51,086.40 |
DisclosureSEC source: 0000950170-24-095402 · ownership.xml · nonDerivative · entry 6 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 6,232,959 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.995 to $44.06, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 40,268 | $43.44 | $1,749,241.92 |
DisclosureSEC source: 0000950170-24-095402 · ownership.xml · nonDerivative · entry 5 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 6,234,119 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.99 to $43.98, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 50,736 | $42.55 | $2,158,816.80 |
DisclosureSEC source: 0000950170-24-095402 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 6,274,387 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.985 to $42.98, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 09, 2024 Filed Aug 14, 2024 20:05 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,160 | $44.04 | $51,086.40 |
DisclosureSEC source: 0000950170-24-096987 · ownership.xml · nonDerivative · entry 6 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,866,166 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.995 to $44.06, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 09, 2024 Filed Aug 14, 2024 20:05 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 40,268 | $43.44 | $1,749,241.92 |
DisclosureSEC source: 0000950170-24-096987 · ownership.xml · nonDerivative · entry 5 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,867,326 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.99 to $43.98, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 09, 2024 Filed Aug 14, 2024 20:05 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 50,736 | $42.55 | $2,158,816.80 |
DisclosureSEC source: 0000950170-24-096987 · ownership.xml · nonDerivative · entry 4 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,907,594 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.985 to $42.98, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 68,936 | $42.87 | $2,955,286.32 |
DisclosureSEC source: 0000950170-24-095402 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 6,325,123 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.465 to $43.23, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 16,357 | $42.97 | $702,860.29 |
DisclosureSEC source: 0000950170-24-095402 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 6,394,059 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.605 to $42.435, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 6,377 | $40.74 | $259,798.98 |
DisclosureSEC source: 0000950170-24-095402 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 6,410,416 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $40.60 to $41.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2024 Filed Aug 14, 2024 20:05 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 68,936 | $42.87 | $2,955,286.32 |
DisclosureSEC source: 0000950170-24-096987 · ownership.xml · nonDerivative · entry 3 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,958,330 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.465 to $43.23, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2024 Filed Aug 14, 2024 20:05 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 16,357 | $42.97 | $702,860.29 |
DisclosureSEC source: 0000950170-24-096987 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 2,027,266 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.605 to $42.435, inclusive. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| August 08, 2024 Filed Aug 14, 2024 20:05 UTC Amendment | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 6,377 | $40.74 | $259,798.98 |
DisclosureSEC source: 0000950170-24-096987 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 2,043,623 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. ("FCF IV") on April 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $40.60 to $41.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4. F3 · ownership.nature: The shares are held directly by FCF IV. Forbion IV Management B.V. ("Forbion Management"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 25,133 | $0.00 Strike: $31.53 | $0.00 |
DisclosureSEC source: 0000950170-24-064728 · ownership.xml · derivative · entry 1 Kersten Dirk · CIK 0001823682 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,133 Underlying: Common Stock · 25,133 shares Expires 2034-05-21 F1 · derivative.exercise_date: This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 1,428,571 | $17.50 | $24,999,992.50 |
DisclosureSEC source: 0000950170-24-003943 · ownership.xml · nonDerivative · entry 2 Kersten Dirk · CIK 0001823682 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,428,571 F2 · ownership.nature: The shares are held directly by Forbion Growth Opportunities Fund II Cooperatief U.A ("FGO II "). Forbion Growth II Management B.V. ("FGO II Management") the director of FGO II, may be deemed to have voting and dispositive power over the shares held by FGO II. Investment decisions with respect to the shares held by FGO II can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FGO II. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 285,714 | $17.50 | $4,999,995.00 |
DisclosureSEC source: 0000950170-24-003943 · ownership.xml · nonDerivative · entry 1 Kersten Dirk · CIK 0001823682 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,416,793 F1 · ownership.nature: The shares are held directly by Forbion Capital Fund IV Cooperatief U.A ("FCF IV"). Forbion IV Management B.V. ("Forbion Management") the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the "Partners") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 24, 2023 Filed May 25, 2023 22:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 24,900 | $0.00 Strike: $13.49 | $0.00 |
DisclosureSEC source: 0001209191-23-032276 · doc4.xml · derivative · entry 1 Kersten Dirk · CIK 0001823682 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.